Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
8.70
-0.06 (-0.68%)
Oct 8, 2025, 9:53 AM EDT - Market open
Company Description
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism.
The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.
Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Rezolute, Inc.
| Country | United States |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 71 |
| CEO | Nevan Elam |
Contact Details
Address: 275 Shoreline Drive, Suite 500 Redwood City, California 94065 United States | |
| Phone | 650 206 4507 |
| Website | rezolutebio.com |
Stock Details
| Ticker Symbol | RZLT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001509261 |
| CUSIP Number | 76200L309 |
| ISIN Number | US76200L3096 |
| Employer ID | 27-3440894 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nevan Charles Elam J.D. | Founder, Chief Executive Officer, Principal Financial Officer and Acting Chairman of the Board |
| Daron G. Evans M.B.A., M.S. | Chief Financial Officer |
| Dr. Brian Kenneth Roberts M.D. | Chief Medical Officer |
| Michael R. Deperro | Senior Vice President and Head of Operations |
| Dr. Davelyn Eaves Hood M.B.A., M.D. | Director and Head of Scientific and Patient Affairs |
| Michael Covarrubias | Senior Vice President and Head of Program & Portfolio Management |
| Chris Milks | Vice President and Head of Finance |
| Dr. Raj Agrawal M.D. | Vice President and Head of Ophthalmological Clinical Development |
| Robyn Sweinhart | Vice President and Head of Quality |
| Erin O'Boyle | Senior Vice President and Head of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 7, 2025 | DEF 14A | Other definitive proxy statements |
| Sep 22, 2025 | SCHEDULE 13G | Filing |
| Sep 17, 2025 | 10-K | Annual Report |
| Sep 17, 2025 | 8-K | Current Report |
| Sep 2, 2025 | 8-K | Current Report |
| Aug 20, 2025 | 8-K | Current Report |
| Aug 8, 2025 | EFFECT | Notice of Effectiveness |
| Aug 6, 2025 | SCHEDULE 13G/A | Filing |
| Jul 24, 2025 | UPLOAD | Filing |
| Jul 18, 2025 | 8-K | Current Report |